|drug163||Acetylsalicylic acid Wiki||1.00|
|D016769||Embolism and Thrombosis NIH||0.50|
There is one clinical trial.
Our aim is to conduct a pilot single-blind randomized controlled trial to examine the preliminary efficacy of a 14 day app-based pulmonary and mobility focused rehabilitation program (intervention arm) versus a self-guided exercise program (active control arm) on pulmonary and functional outcomes in 100 patients tested for COVID-19 infection and isolated at home.
Description: The SGRQ is a valid instrument for measuring pulmonary function in patients with respiratory disease, with a total score and scores for symptom, physical activity, and impact domains (range 0 to 100; higher scores worse). The minimum clinically important difference is 4 points. The questionnaire has excellent reliability and validity compared to gold standard pulmonary function tests.Measure: Change in pulmonary function (St George's Respiratory questionnaire: SGRQ) Time: baseline, at day 7 and at day 14
Description: The AM-PAC was developed to examine basic mobility and daily activity functional activities important to adults. It is a validated measure of patient-reported functional limitation in 3 domains: basic mobility, daily activities, and applied cognition. It is endorsed by the National Quality Forum as a functional status quality metric.Measure: Change in physical function (Activity Measure for Post-Acute Care: AM-PAC) Time: baseline, at day 7 and at day 14
Description: Patient asked to take a deep breath while at rest and to hold it (Normal >25 s). Test monitored by video (Zoom, PT-Pal).Measure: Change in pulmonary function (Sabrasez single breath count) Time: baseline, at day 7 and at day 14
Description: Participants will be given a peak flow meter at recruitment, and taught how to use it by research staff over video.Measure: Change in pulmonary function (Peak flow tests) Time: baseline, at day 7 and at day 14
Description: This timed test assesses strength, balance and endurance. Test monitored by video (Zoom, PT-Pal).Measure: Change in physical function (5 times site to stand test) Time: baseline, at day 7 and at day 14
Description: Self-report or information from medical staff.Measure: Health events (emergency room visits and hospitalizations) Time: baseline to day 14
Description: Anxiety symptoms reported on the BAI. Higher scores indicate more anxiety.Measure: Change in psychological measures (Beck Anxiety Inventory: BAI) Time: baseline, at day 7 and at day 14
Description: Depressive symptoms reported on the CES-D. Higher score indicate more depressive symptoms.Measure: Change in psychological measures (Center for Epidemiologic Studies Depression Scale: CES-D) Time: baseline, at day 7 and at day 14
Description: Number of sessions completed using app in the intervention arm. Controls periodically interviewed.Measure: Feasibility (Adherence) Time: baseline to day 14
Description: Survey of satisfaction with exercise programs.Measure: Feasibility (Acceptability) Time: baseline to day 14
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports